Most Read Articles
Dr. Karl Csaky, Dr. Charles Wykoff, Dr. Jeffrey Heier, 08 Apr 2021
Intravitreal injections with anti-vascular endothelial growth factor (VEGF) agents are associated with significant treatment burden for patients with diabetic macular oedema (DME) and neovascular age-related macular degeneration (nAMD). At the Angiogenesis, Exudation, and Degeneration 2021 Virtual Congress, Dr Karl Csaky of Retina Foundation of the Southwest, Dallas, Texas, US, Dr Charles Wykoff of Retina Consultants of Texas, Houston, Texas, US, and Dr Jeffrey Heier of Ophthalmic Consultants of Boston, Boston, Massachusetts, US, presented results of four phase III trials that compared the efficacy and safety of the investigational bispecific antibody, faricimab, administered at up to Q16W dosing intervals, vs the decoy VEGF-A/placental growth factor (PIGF) receptor aflibercept at Q8W dosing intervals, in patients with retinal vascular diseases.

Dexamethasone implants stall but do not reverse VA loss in macular oedema after RVO

22 Apr 2021

Dexamethasone intravitreal implants (DII) can help maintain visual acuity (VA) in patients with macular oedema (ME) due to retinal vein occlusion (RVO) but cannot seem to reverse VA loss, a recent study has found.

Electronic medical records of 99 patients (median age 75.36 years, 51 men) with ME after RVO were accessed; all participants had received DII. Most were not treatment-naïve, with 61 eyes (62 percent) having received prior triamcinolone (TAC), while another 15 eyes (15 percent) had been treated with additional antivascular endothelial growth factor (VEGF) agent. DII was considered first-line in only 17 eyes.

Over a mean follow-up of 312±310 days, a total of 28 eyes (28 percent) achieved treatment success, defined as resolved ME without rebound for at least 3 months. Forty-seven eyes saw no benefit from DII and were either withdrawn from treatment or needed a different course of action.

Morphologically, mean central retinal thickness (CRT) dropped to 431±199 µm at the end of the observation period from 526±179 µm at baseline. The mean reduction values in CRT were 95, 65, and 95 µm after 1, 2, and 3 years, respectively.

Despite a notable change in eye structure, the researchers documented no associated functional effects. Mean VA was mostly maintained, decreasing only slightly from 66.7±23.5 letters at baseline to 64.9±28.3 letters at the last observation.

Intraocular pressure was likewise stable, rising marginally from 14.4±3.1 mm Hg at baseline to 17.1±6.3 mm Hg at the final observation.

“[O]ur study reports real-life effects of intravitreal dexamethasone treatment in patients with ME following RVO,” the researchers said. “The reported data may help to give patients and health care providers guidelines on what can be expected with regard to VA and CRT development in this important indication.”

Editor's Recommendations
Most Read Articles
Dr. Karl Csaky, Dr. Charles Wykoff, Dr. Jeffrey Heier, 08 Apr 2021
Intravitreal injections with anti-vascular endothelial growth factor (VEGF) agents are associated with significant treatment burden for patients with diabetic macular oedema (DME) and neovascular age-related macular degeneration (nAMD). At the Angiogenesis, Exudation, and Degeneration 2021 Virtual Congress, Dr Karl Csaky of Retina Foundation of the Southwest, Dallas, Texas, US, Dr Charles Wykoff of Retina Consultants of Texas, Houston, Texas, US, and Dr Jeffrey Heier of Ophthalmic Consultants of Boston, Boston, Massachusetts, US, presented results of four phase III trials that compared the efficacy and safety of the investigational bispecific antibody, faricimab, administered at up to Q16W dosing intervals, vs the decoy VEGF-A/placental growth factor (PIGF) receptor aflibercept at Q8W dosing intervals, in patients with retinal vascular diseases.